Therapeutic angiogenesis using vascular endothelial growth factor

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Molecular Biology

Background:

• Tissue ischemia, often seen in heart disease, results from inadequate blood supply.
• Therapeutic angiogenesis aims to restore blood flow by stimulating new blood vessel formation.
• Vascular Endothelial Growth Factor (VEGF) is a key signaling protein in natural angiogenesis.

Purpose of the Study:

• To review the role of VEGF in therapeutic angiogenesis for treating ischemic conditions.
• To discuss the methods, challenges, and potential of VEGF-based therapies.
• To evaluate the clinical progress of therapeutic angiogenesis in ischemic heart disease.

Main Methods:

• Review of scientific literature on VEGF and angiogenesis.
• Analysis of preclinical animal studies demonstrating neovascularization and improved perfusion.
• Examination of Phase I and II clinical trial data for safety and efficacy.

Main Results:

• VEGF stimulates endothelial cell proliferation, migration, and mobilization of progenitor cells.
• Gene and protein-based delivery methods have been employed for VEGF administration.
• Animal models show significant neovascularization and enhanced myocardial perfusion.
• Early clinical trials indicate encouraging safety and efficacy profiles.

Conclusions:

• Therapeutic angiogenesis with VEGF shows significant potential for treating ischemic heart disease.
• Further research and clinical development are needed to address challenges and optimize treatment strategies.
• VEGF-based therapies represent a promising clinical modality for cardiovascular regeneration.